Navigation Links
Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
Date:12/20/2010

More effective risk-adjusted chemotherapy and sophisticated patient monitoring helped push cure rates to nearly 88 percent for older adolescents enrolled in a St. Jude Children's Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and closed the survival gap between older and younger patients battling the most common childhood cancer.

A report online in the December 20 edition of the Journal of Clinical Oncology noted that overall survival jumped 30 percent in the most recent treatment era for ALL patients who were age 15 through 18 when their cancer was found.

The study compared long-term survival of patients treated between 2000 and 2007 in a protocol designed by St. Jude investigators with those enrolled in earlier St. Jude protocols. About 59 percent of older patients treated between 1991 and 1999 were cured, compared with more than 88 percent of children ages 1 through 14 treated during the same period. But overall survival for older patients rose to almost 88 percent between 2000 and 2007, when long-term survival of younger patients soared to about 94 percent. Nationally, about 61 percent of ALL patients age 15 to 19 treated between 2000 and 2004 were still alive five years later.

Not only did more patients in the recent treatment era survive, but Ching-Hon Pui, M.D., chair of the St. Jude Department of Oncology and the paper's lead author, said they are also less likely to suffer serious late treatment effects, including second cancers and infertility. That is because the regimen, known as Total XV, eliminated or dramatically reduced reliance on drugs associated with those side effects.

The protocol also replaced radiation of the brain with chemotherapy as a strategy for preventing relapse in the central nervous system and for reducing the risk of later neuro-cognitive problems. None of the adolescents suffered central nervous system relapses. "Not only have we increased the cure rate, but we hav
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
2. Texas Girl Recovers From Rabies Without Intensive Care
3. Risk for patients in the intensive care unit clearly reduced
4. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
5. Children in Intensive Care Should Be Screened for MRSA
6. Intensively lowering glucose: Possible benefits must be weighed against risks
7. Researchers uncover biological rationale for why intensive lupus treatment works
8. Neonatal intensive care units critical to infant survival
9. Intensive care diaries protect patients from PTSD
10. University Hospitals Case Medical Centers neuroscience intensive care unit earns Beacon Award
11. Once upon a time in the Intensive Care Unit ...
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ZH Healthcare announces ... 2015. , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare ... as a service (SaaS). , HITaaS manages all aspects of infrastructure, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Women's Excellence ... for Natural Birth . The Karmanos Center for Natural Birth provides a ... With nurses and caregivers that are trained in holistic birth approaches, patients can ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Physical therapy for knee osteoarthritis ... patient's quality of life. It keeps the patient from doing what they want or need ... have a hard time using the stairs. The patient's exercise regime may be limited by ...
(Date:7/31/2015)... ... 2015 , ... EB Medicine, leading publisher of clinical journals, ... to announce that it has partnered with AgileMD to release Pediatric Emergency ... Android smartphones and tablets. , “The April 2015 launch of our flagship ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers invites the public ... Oregon August 15th, 2015 from 9am – 12pm. Timber frame raisings are ... the entire community as the culmination of months of effort, planning, fundraising, and dreaming ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
(Date:7/31/2015)...  Semler Scientific, Inc. (Nasdaq: SMLR ), a ... insurers and physician groups, today reported financial results for ... "In the second quarter of 2015, Semler reported ... 54%, quarter over quarter revenue growth of 8%, and ... FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., chief ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
Incontinence Pessaries...
Medicine Products: